You need pivotal trials Doc. These past phase 1 with 40n aren't pivotals. Nwbo will need to work with the fda once gbm is approved in designing such pivotal or registration trials. That's how this works. Whether these are basket trials consisting of multiple indications or whether they are single arm cohorts....there needs to a defined registrational path.
ATLinsider figured out how it works. I will credit where credit is due.
Market Data 
Markets 
AI
